{"id":4150,"date":"2021-08-17T12:37:20","date_gmt":"2021-08-17T12:37:20","guid":{"rendered":"http:\/\/www.sarmsthailand.com\/?post_type=product&p=4150"},"modified":"2026-07-26T05:29:29","modified_gmt":"2026-07-26T05:29:29","slug":"nolvadex-50-tablets-sarms-pct","status":"publish","type":"product","link":"https:\/\/www.sarmsthailand.com\/th\/product\/nolvadex-50-tablets-sarms-pct\/","title":{"rendered":"Nolvadex 20 mg for SARM PCT (50 Tablets)"},"content":{"rendered":"
\n

Buy Nolvadex for SARM PCT in Thailand<\/h2>\n

Nolvadex comes in a bottle of 50 tablets, with each tablet containing 20 mg of tamoxifen. It is commonly considered by customers researching post-cycle support after a suppressive SARM cycle.<\/p>\n

This product contains tamoxifen and is sold under the familiar Nolvadex name. The information on this page is focused specifically on SARM PCT and post-cycle hormone support after SARMs.<\/p>\n

\n

Nolvadex Product Specifications<\/h2>\n
\n\n\n\n\n\n\n\n\n\n
Product<\/th>\nNolvadex \/ Tamoxifen<\/td>\n<\/tr>\n
Active ingredient<\/th>\nTamoxifen, provided as tamoxifen citrate<\/td>\n<\/tr>\n
Strength<\/th>\n20 mg tamoxifen per tablet<\/td>\n<\/tr>\n
Quantity<\/th>\n50 tablets<\/td>\n<\/tr>\n
Format<\/th>\nOral tablets<\/td>\n<\/tr>\n
Product class<\/th>\nSelective estrogen receptor modulator<\/td>\n<\/tr>\n
Site category<\/th>\nSARM PCT and post-cycle support<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n

What Is Nolvadex?<\/h2>\n

Nolvadex is the familiar market name for tamoxifen, an oral selective estrogen receptor modulator commonly abbreviated as a SERM.<\/p>\n

Tamoxifen interacts selectively with estrogen receptors in different tissues. It is not a SARM and does not work through the same pathway as Ostarine, LGD-4033, RAD-140 or other selective androgen receptor modulators.<\/p>\n

Why Nolvadex Is Used for SARM PCT<\/h2>\n

Some SARM cycles can reduce the hormonal signals involved in maintaining natural testosterone production. The degree of suppression can vary according to the SARM, cycle duration, exposure and individual response.<\/p>\n

Nolvadex is commonly considered for SARM PCT because tamoxifen can influence estrogen feedback at the hypothalamus and pituitary gland. Human research in men has reported increases in luteinizing hormone, follicle-stimulating hormone and testosterone during tamoxifen treatment.<\/p>\n

This makes Nolvadex relevant to customers researching post-cycle support after compounds such as LGD-4033 Ligandrol<\/a>, RAD-140 Testolone<\/a> and Ostarine MK-2866<\/a>.<\/p>\n

Does Nolvadex Lower Estrogen?<\/h2>\n

Nolvadex is often described informally as an estrogen blocker, but that description can be misleading. Tamoxifen does not directly stop the body from producing estrogen or necessarily reduce the amount of estrogen in the blood.<\/p>\n

Instead, tamoxifen selectively changes how estrogen communicates with receptors in particular tissues. This makes Nolvadex different from products that work by reducing estrogen production.<\/p>\n

Human Tamoxifen Research in Men<\/h2>\n

Controlled research in men has reported that tamoxifen can increase LH, FSH and testosterone through its effects on hormonal feedback signalling.<\/p>\n

Additional research involving men with fertility-related conditions has also reported increases in testosterone and gonadotropin levels during oral tamoxifen treatment.<\/p>\n

These studies support the explanation of tamoxifen\u2019s hormonal mechanism, but they did not investigate a standardized PCT protocol following SARMs. Individual post-cycle requirements can differ.<\/p>\n

Nolvadex Compared With Clomid<\/h2>\n

Nolvadex contains tamoxifen, while Clomid contains clomiphene citrate. Both belong to the SERM category, but they are different compounds with different receptor profiles.<\/p>\n

Clomid is commonly selected when the primary goal is broader stimulation of LH and FSH signalling. Customers comparing the two options can review Clomid 50 mg for SARM PCT<\/a>.<\/p>\n

Nolvadex Compared With Enclomiphene<\/h2>\n

Enclomiphene is the trans-isomer found within clomiphene citrate, whereas Nolvadex contains tamoxifen. They should not be treated as different names for the same product.<\/p>\n

Customers looking for an alternative focused on endogenous testosterone signalling can compare Enclomiphene 25 mg for SARM PCT<\/a>.<\/p>\n

Planning Post-Cycle Support After SARMs<\/h2>\n

No single post-cycle plan is appropriate after every SARM cycle. The compound used, duration, exposure, previous cycles and individual hormone levels can all influence the recovery process.<\/p>\n

Blood testing before and after a SARM cycle provides more useful information than relying only on symptoms. Commonly reviewed markers include total testosterone, free testosterone, luteinizing hormone, follicle-stimulating hormone and estradiol.<\/p>\n

The fixed four-week dosage schedule currently shown on this page should be removed because SARM PCT requirements are not identical for every customer.<\/p>\n

Is Nolvadex a SARM?<\/h2>\n

No. Nolvadex is a selective estrogen receptor modulator. It appears within the SARM PCT category because tamoxifen is commonly considered for post-cycle support after SARMs.<\/p>\n

Frequently Asked Questions<\/h2>\n

How many Nolvadex tablets are included?<\/h3>\n

Each bottle contains 50 tablets, with 20 mg of tamoxifen in each tablet.<\/p>\n

Is Nolvadex the same as Tamoxifen?<\/h3>\n

Tamoxifen is the active compound associated with the Nolvadex name. Generic tamoxifen products may contain the same active ingredient without being manufactured under the original pharmaceutical brand.<\/p>\n

Is Nolvadex an estrogen blocker?<\/h3>\n

Nolvadex selectively modulates estrogen receptors rather than directly stopping estrogen production. Selective estrogen receptor modulator is the more accurate description.<\/p>\n

Does every SARM cycle require Nolvadex?<\/h3>\n

No. Post-cycle requirements depend on the SARM used, individual hormonal response and relevant blood-test results. The same approach should not automatically be applied after every cycle.<\/p>\n

Independent Information Sources<\/h2>\n